Correction to: Imipenem–Relebactam and Meropenem–Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations

被引：0
|
作者：
George G. Zhanel
Courtney K. Lawrence
Heather Adam
Frank Schweizer
Sheryl Zelenitsky
Michael Zhanel
Philippe R. S. Lagacé-Wiens
Andrew Walkty
Andrew Denisuik
Alyssa Golden
Alfred S. Gin
Daryl J. Hoban
Joseph P. Lynch
James A. Karlowsky
机构：
[1] University of Manitoba,Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine
[2] University of Manitoba,College of Pharmacy
[3] University of Manitoba,Department of Chemistry, Faculty of Science
[4] Winnipeg Health Sciences Centre,Department of Medicine
[5] Winnipeg Health Sciences Centre,Department of Pharmacy
[6] Diagnostic Services Manitoba,Division of Pulmonary, Critical Care, Allergy and Clinical Immunology
[7] The David Geffen School of Medicine at UCLA,undefined
来源：
Drugs | 2018年 / 78卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Section heading 5.2, which currently reads 5.2 Meropenem–Relebactam.
引用
收藏
页码：787 / 787
相关论文
共 50 条
  • [41] Klebsiella pneumoniae Susceptibility to Carbapenem/Relebactam Combinations: Influence of Inoculum Density and Carbapenem-to-Inhibitor Concentration Ratio
    Golikova, Maria, V
    Alieva, Kamilla N.
    Filimonova, Alla, V
    Ageevets, Vladimir A.
    Sulian, Ofeliia S.
    Avdeeva, Alisa A.
    Sidorenko, Sergey, V
    Zinner, Stephen H.
    BIOMEDICINES, 2022, 10 (06)
  • [42] Discovery of a Novel Metallo-β-Lactamase Inhibitor That Potentiates Meropenem Activity against Carbapenem-Resistant Enterobacteriaceae
    Everett, Martin
    Sprynski, Nicolas
    Coelho, Alicia
    Castandet, Jerome
    Bayet, Maelle
    Bougnon, Juliette
    Lozano, Clarisse
    Davies, David T.
    Leiris, Simon
    Zalacain, Magdalena
    Morrissey, Ian
    Magnet, Sophie
    Holden, Kirsty
    Warn, Peter
    De Luca, Filomena
    Docquier, Jean-Denis
    Lemonnier, Marc
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (05)
  • [43] Synergistic effect of the novel beta-lactamase inhibitor BLI-489 combined with imipenem or meropenem against diverse carbapenemase-producing carbapenem-resistant Enterobacterales
    Shi, Shiyi
    Zhang, Xiaodong
    Yao, Zhuocheng
    Xu, Mengxin
    Zhou, Beibei
    Liu, Qi
    Zhang, Ying
    Zhou, Cui
    Zhou, Tieli
    Ye, Jianzhong
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2022, 77 (05) : 1301 - 1305
  • [44] Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants
    Rhee, Elizabeth G.
    Rizk, Matthew L.
    Calder, Nicole
    Nefliu, Marcela
    Warrington, Steven J.
    Schwartz, Michael S.
    Mangin, Eric
    Boundy, Keith
    Bhagunde, Pratik
    Colon-Gonzalez, Francheska
    Jumes, Patricia
    Liu, Yang
    Butterton, Joan R.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (09)
  • [45] Clonal dissemination of Klebsiella pneumoniae resistant to cefiderocol, ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam co-producing KPC and OXA-181 carbapenemase
    Bovo, Federica
    Amadesi, Stefano
    Palombo, Marta
    Lazzarotto, Tiziana
    Ambretti, Simone
    Gaibani, Paolo
    JAC-ANTIMICROBIAL RESISTANCE, 2023, 5 (04):
  • [46] Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections
    Sader, Helio S.
    Castanheira, Mariana
    Duncan, Leonard R.
    Mendes, Rodrigo E.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2021, 113 : 279 - 281
  • [47] Epidemiology and in vitro activity of ceftazidime–avibactam, meropenem–vaborbactam, imipenem–relebactam, eravacycline, plazomicin, and comparators against Greek carbapenemase-producing Klebsiella pneumoniae isolates
    Sofia Maraki
    Viktoria Eirini Mavromanolaki
    Eleni Magkafouraki
    Panagiotis Moraitis
    Dimitra Stafylaki
    Anna Kasimati
    Effie Scoulica
    Infection, 2022, 50 : 467 - 474
  • [48] Relebactam Is a Potent Inhibitor of the KPC-2 β-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae
    Papp-Wallace, Krisztina M.
    Barnes, Melissa D.
    Alsop, Jim
    Taracila, Magdalena A.
    Bethel, Christopher R.
    Becka, Scott A.
    van Duin, David
    Kreiswirth, Barry N.
    Kaye, Keith S.
    Bonomo, Robert A.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (06)
  • [49] In vitro activity of imipenem/relebactam, meropenem/vaborbactam and comparators against Pseudomonas aeruginosa in Taiwan: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) in 2020
    Liu, Yuag-Meng
    Ko, Wen-Chien
    Ho, Mao-Wang
    Lee, Yu-Lin
    Hsueh, Po-Ren
    JOURNAL OF INFECTION, 2023, 86 (01) : 75 - 78
  • [50] Imipenem-Cilastatin-Relebactam: A Novel β-Lactam-β-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections
    Smith, Jordan R.
    Rybak, Jeffrey M.
    Claeys, Kimberly C.
    PHARMACOTHERAPY, 2020, 40 (04): : 343 - 356
12345